An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

NCT00242736 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
350
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AstraZeneca